国产午夜福利片1000无码丨人妻国产成人久久av免费高清丨午夜做受视频试看6次丨日韩av不卡一区在线免费观看丨在线观看精品三级欧美

Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Xylella fastidiosa UPF0133 protein XfasM23_1122 (XfasM23_1122) CSB-YP458231XBN
CSB-EP458231XBN
CSB-BP458231XBN
CSB-MP458231XBN
CSB-EP458231XBN-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xylella fastidiosa Bis (5'-nucleosyl)-tetraphosphatase, symmetrical CSB-YP458232XBN
CSB-EP458232XBN
CSB-BP458232XBN
CSB-MP458232XBN
CSB-EP458232XBN-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xylella fastidiosa Elongation factor P-like protein (XfasM23_1338) CSB-YP458233XBN
CSB-EP458233XBN
CSB-BP458233XBN
CSB-MP458233XBN
CSB-EP458233XBN-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xylella fastidiosa ATP phosphoribosyltransferase (hisG) CSB-YP458234XBN
CSB-EP458234XBN
CSB-BP458234XBN
CSB-MP458234XBN
CSB-EP458234XBN-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xylella fastidiosa Elongation factor 4 (lepA), partial CSB-YP458235XBN
CSB-EP458235XBN
CSB-BP458235XBN
CSB-MP458235XBN
CSB-EP458235XBN-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xylella fastidiosa 5-methyltetrahydropteroyltriglutamate--homocysteine methyltransferase (metE), partial CSB-YP458236XBN
CSB-EP458236XBN
CSB-BP458236XBN
CSB-MP458236XBN
CSB-EP458236XBN-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xylella fastidiosa 4-hydroxybenzoate octaprenyltransferase (ubiA), partial CSB-YP458237XBN
CSB-EP458237XBN
CSB-BP458237XBN
CSB-MP458237XBN
CSB-EP458237XBN-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xylella fastidiosa Ribosomal RNA large subunit methyltransferase E (rlmE) CSB-YP458238XBN
CSB-EP458238XBN
CSB-BP458238XBN
CSB-MP458238XBN
CSB-EP458238XBN-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xylella fastidiosa Succinyl-diaminopimelate desuccinylase (dapE) CSB-YP458239XBN
CSB-EP458239XBN
CSB-BP458239XBN
CSB-MP458239XBN
CSB-EP458239XBN-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xylella fastidiosa Protein grpE (grpE) CSB-YP458240XBN
CSB-EP458240XBN
CSB-BP458240XBN
CSB-MP458240XBN
CSB-EP458240XBN-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xylella fastidiosa NADPH-dependent 7-cyano-7-deazaguanine reductase (queF) CSB-YP458241XBN
CSB-EP458241XBN
CSB-BP458241XBN
CSB-MP458241XBN
CSB-EP458241XBN-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xylella fastidiosa Probable cytosol aminopeptidase (pepA) CSB-YP458242XBN
CSB-EP458242XBN
CSB-BP458242XBN
CSB-MP458242XBN
CSB-EP458242XBN-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xylella fastidiosa Phosphoribosylaminoimidazole-succinocarboxamide synthase (purC) CSB-YP458243XBN
CSB-EP458243XBN
CSB-BP458243XBN
CSB-MP458243XBN
CSB-EP458243XBN-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xylella fastidiosa Lipoprotein signal peptidase (lspA), partial CSB-YP458244XBN1
CSB-EP458244XBN1
CSB-BP458244XBN1
CSB-MP458244XBN1
CSB-EP458244XBN1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xylella fastidiosa 3-methyl-2-oxobutanoate hydroxymethyltransferase (panB) CSB-YP458245XBN
CSB-EP458245XBN
CSB-BP458245XBN
CSB-MP458245XBN
CSB-EP458245XBN-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xylella fastidiosa NADH-quinone oxidoreductase subunit D (nuoD) CSB-YP458246XBN
CSB-EP458246XBN
CSB-BP458246XBN
CSB-MP458246XBN
CSB-EP458246XBN-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xylella fastidiosa Shikimate dehydrogenase (aroE) CSB-YP458247XBN
CSB-EP458247XBN
CSB-BP458247XBN
CSB-MP458247XBN
CSB-EP458247XBN-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xylella fastidiosa Sec-independent protein translocase protein TatA (tatA), partial CSB-YP458248XBN
CSB-EP458248XBN
CSB-BP458248XBN
CSB-MP458248XBN
CSB-EP458248XBN-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xylella fastidiosa Ribonuclease HII (rnhB) CSB-YP458249XBN
CSB-EP458249XBN
CSB-BP458249XBN
CSB-MP458249XBN
CSB-EP458249XBN-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xylella fastidiosa GTPase Der (der) CSB-YP458250XBN
CSB-EP458250XBN
CSB-BP458250XBN
CSB-MP458250XBN
CSB-EP458250XBN-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://www.jhhuazhong.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>